Chapter 8 242 cohort, both the clinical effect of vaccination on PASC symptomatology and antibody kinetics between those with and without PASC over time. Using longitudinal data from a prospective cohort study of COVID-19 patients enrolled at disease onset, we assessed the effect of vaccination on recovery from PASC symptoms. This analysis is complemented by immunological investigations to assess possible associations between antibody kinetics prior to vaccination and development of PASC. METHODS Study population RECoVERED is a cohort study of individuals with SARS-CoV-2 infection in the municipal region of Amsterdam, the Netherlands. The aims of this cohort are to describe the immunological, clinical and psychosocial sequelae of SARS-CoV-2 infection across the full spectrum of COVID-19 severity. Enrolment of study participants occurred between 11 May 2020 and 21 June 2021. Study design and procedures have been described in detail elsewhere[1]. Briefly, non-hospitalised patients were selected from notified cases of SARSCoV-2 infection at the Public Health Service of Amsterdam, and invited to participate within 7 days of diagnosis by means of a telephone call by trained study staff. Prospectivelyenrolled hospitalised participants were identified from admissions to the COVID-19 wards and enrolled within 7 days of hospital admission at the Amsterdam University Medical Centres (UMC) by means of a bedside visit on the hospital ward or a telephone call, if already discharged from hospital. Eligibility criteria included laboratory confirmation of SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT-PCR), age 1685 years, residing in the municipal region of Amsterdam, and adequate understanding of Dutch or English. Individuals residing in a nursing home and those with mental disorders deemed likely to interfere to adherence to study procedures were excluded. For the current analysis, we included RECoVERED participants with at least 3 months of follow-up after illness onset and used follow-up data collected up to 1 November 2021. RECoVERED was approved by the medical ethical review board of the Amsterdam University Medical Centres (NL73759.018.20). All participants provided written informed consent. Study procedures During the first month of follow-up, trained study staff interviewed participants on the presence, severity, and start and stop dates of 20 different COVID-19 symptoms, took
RkJQdWJsaXNoZXIy MTk4NDMw